uniQure’s (NASDAQ: QURE ) stock skyrocketed in late September after the announcement of stronger-than-expected Huntington’s trial data. Despite a more than 300% increase in the share price, the market still seems to be undervaluing uniQure, which likely stems from uncertainty around the validity of theRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess ...

uniQure N.V. (NASDAQ:QURE) is one of the stocks Jim Cramer recently talked about. A caller asked whether to buy, hold, or take profits in the stock after the release of clinical data, which indicated its gene therapy candidate significantly slowed the progression of Huntington’s disease. Cramer said: “Yeah, I saw that news and it was really terrific. But I also saw that an insider sold about $9 million worth of stock after the run. I think that’s a, it’s a parabola, and after a parabolic move, I will not ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended being careful with Ambiq Micro, Inc. (NYSE:AMBQ). He added, “There are so many good semiconductor companies out there” and recommended going with Broadcom (NASDAQ:AVGO).On the earnings front, Ambiq Micro reported quarterly losses of 43 cents per share on sales of $17.90 million on Sept. 4.Cramer said he doesn't like Albertsons Companies, Inc. (NYSE:ACI) here.RBC Capital analyst Steven Shemesh, on Oct. 3, maintained Albertsons Companies with an Ou ...

Ambiq Micro (AMBQ) - Jim Cramer建议谨慎对待Ambiq Micro，并推荐博通等其他半导体公司[1] - 公司于9月4日公布季度财报，每股亏损0.43美元，销售额为1790万美元[1] - 公司股价上周五上涨0.5%，收于29.83美元[7] Albertsons Companies (ACI) - Jim Cramer表示不喜欢Albertsons Companies[1] - RBC Capital分析师Steven Shemesh于10月3日维持公司“跑赢大盘”评级，但将目标价从23美元下调至21美元[2] - 公司股价上周五上涨0.2%，收于17.38美元[7] uniQure N.V. (QURE) - Jim Cramer在股价出现抛物线走势后不予背书，认为存在太多疑问[2] - Wells Fargo分析师Yanan Zhu于10月2日维持公司“增持”评级，并将目标价从65美元上调至80美元[2] - 公司股价上周五上涨0.8%，收于54.92美元[7] Chevron Corporation (CVX) - Jim Cramer认为可以持有该公司，但表示不是石油行业粉丝，预计油价可能跌破60美元[3] - Mizuho分析师Nitin Kumar于9月15日维持公司“跑赢大盘”评级，将目标价从192美元微降至191美元[3] - 公司股价上周五上涨0.1%，收于153.55美元[7] LCI Industries (LCII) - Jim Cramer推荐买入LCI Industries[3] - 公司于8月5日公布第二季度财报，业绩超预期[3] - 公司股价上周五上涨1.0%，收于94.41美元[7] Dillard's, Inc. (DDS) - Jim Cramer建议部分获利了结，部分继续持有[4] - 公司于8月14日公布第二季度财报，业绩超预期[4] - 公司股价上周五下跌1.2%，收于616.25美元[7]

公司股价表现 - 生物技术公司uniQure股价在9月24日单日飙升284% [1] - 股价上涨至54.77美元，当日涨幅0.50% [1] - 52周价格区间为4.82美元至60.70美元 [1] 核心产品与临床试验结果 - 公司专注于开发基因疗法，其治疗亨廷顿病的药物AMT-130取得突破性临床数据 [3] - 在36个月时，AMT-130达到主要终点，高剂量患者亨廷顿病进展显示出统计学上显著的75%减缓 [4] - 基于综合统一亨廷顿病评定量表（cUHDRS）的测量结果，该量表结合了功能、认知和运动测试 [4] - 试验同时达到次要终点，基于总功能容量（TFC）显示疾病进展减缓60% [5] - TFC用于衡量患者独立完成日常任务的能力，此类终点指标在医学研究中备受重视 [5] 分析师观点与价格目标 - 华尔街分析师对AMT-130数据给予积极评价，认为结果“令人惊叹”和“非常鼓舞人心” [7] - 市场共识目标价约为67美元，若排除未更新的目标价，平均目标价上调至73美元，暗示25%的上涨空间 [8] - 最乐观的目标价来自Guggenheim和UBS，均为95美元，意味着较当前股价有约63%的潜在涨幅 [9] - 基于11位分析师评级，12个月平均目标价为68.42美元，当前股价为54.88美元 [6][7] 监管审批与市场潜力 - 公司计划在2026年第一季度提交AMT-130的上市申请 [10] - 公司已在2025年第二季度与FDA达成监管 alignment，FDA同意使用I/II期试验数据评估AMT-130的加速批准，这免除了III期试验的要求 [10] - 分析师对AMT-130获得FDA批准持乐观态度，认为现有数据支持批准，监管风险有限 [11] - 高盛预计AMT-130有90%的概率达到25亿美元的年销售峰值 [11] - 美国大型生物技术和制药股的中位前瞻市销率（P/S）约为5倍，若实现峰值销售预测，公司当前43亿美元的市值有显著上行空间 [11]

ClearPoint Neuro's (NASDAQ: CLPT ) share price recently surged on the back of uniQure's ( QURE ) extremely strong Huntington's data. While the financial impact of AMT-130 should be meaningful, the data is more important as confirmatory evidence of the strength of ClearPoint’sRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can b ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. uniQure N.V. is one of them. uniQure N.V. (NASDAQ:QURE) is a leading gene therapy company focused on developing transformative treatments for severe medical conditions. Its pipeline includes HEMGENIX for hemophilia B and AMT-130, a gene therapy candidate for Huntington’s disease, which has recently attracted significant attention. In late September 2025, uniQure N.V. (NASDAQ:QURE) announced positive topline results ...

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary s ...

智通财经APP获悉，高盛最新深度分析报告聚焦uniQure NV(QURE.US)基因疗法AMT-130在亨廷顿病治 疗中的突破性进展及商业前景。据披露，该疗法已在两项剂量组临床试验中展现显著疗效——高剂量组 17例患者完成36个月随访后，复合亨廷顿病评定量表显示疾病进展较自然病史减缓75%，总功能能力评 分变化减缓60%，脑脊液神经丝轻链蛋白水平平均下降8.2%;低剂量组12例患者虽未直接给出对比数 据，但整体趋势与高剂量组一致。生物标志物及多项次要终点指标均支持AMT-130的神经保护作用。近 日，该股已因为该疗法消息出现大涨。 在FDA加速批准路径下，uniQure计划于2026年第一季度提交生物制品许可申请，基于高剂量组三年期 的复合亨廷顿病评定量表(CUHDRS)变化数据，并采用ENROLL-HD自然病史数据集作为外部对照进行 倾向评分匹配分析。FDA已认可其制造工艺验证路径，要求补充全规模良好生产规范批次及单个工艺性 能确认批次以支持生物制品许可申请(BLA)提交。 安全性方面，自2022年12月起未新增严重不良事件，给药相关不良反应均已解决;第三队列联合免疫抑 制方案试验中，三例严重不良事件通过 ...

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price pe ...